Viking Therapeutics (VKTX) Trading Up 5.3%

Shares of Viking Therapeutics Inc (NASDAQ:VKTX) were up 5.3% on Tuesday . The company traded as high as $8.45 and last traded at $8.39. Approximately 2,770,689 shares traded hands during trading, a decline of 13% from the average daily volume of 3,184,887 shares. The stock had previously closed at $7.97.

Several analysts have commented on the stock. BidaskClub upgraded shares of Viking Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, April 3rd. ValuEngine lowered shares of Viking Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. William Blair reiterated an “outperform” rating on shares of Viking Therapeutics in a report on Friday, March 29th. Leerink Swann upgraded shares of Viking Therapeutics from a “market perform” rating to an “outperform” rating and set a $8.86 target price for the company in a report on Friday, March 29th. Finally, Svb Leerink upgraded shares of Viking Therapeutics from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $10.00 to $21.00 in a report on Friday, March 29th. One research analyst has rated the stock with a sell rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $22.54.

The firm has a market cap of $622.50 million, a PE ratio of -21.45 and a beta of 2.56.



Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.02. Equities analysts predict that Viking Therapeutics Inc will post -0.41 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. ArrowMark Colorado Holdings LLC increased its position in shares of Viking Therapeutics by 18.5% during the first quarter. ArrowMark Colorado Holdings LLC now owns 4,499,204 shares of the biotechnology company’s stock valued at $44,722,000 after acquiring an additional 701,868 shares in the last quarter. BlackRock Inc. increased its position in shares of Viking Therapeutics by 0.4% during the first quarter. BlackRock Inc. now owns 4,114,466 shares of the biotechnology company’s stock valued at $40,896,000 after acquiring an additional 15,060 shares in the last quarter. Vanguard Group Inc increased its position in shares of Viking Therapeutics by 21.4% during the third quarter. Vanguard Group Inc now owns 2,877,287 shares of the biotechnology company’s stock valued at $50,123,000 after acquiring an additional 508,097 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Viking Therapeutics by 21.4% during the third quarter. Vanguard Group Inc. now owns 2,877,287 shares of the biotechnology company’s stock valued at $50,123,000 after acquiring an additional 508,097 shares in the last quarter. Finally, Park West Asset Management LLC increased its position in shares of Viking Therapeutics by 31.8% during the fourth quarter. Park West Asset Management LLC now owns 1,672,507 shares of the biotechnology company’s stock valued at $12,794,000 after acquiring an additional 403,400 shares in the last quarter. 65.72% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://dakotafinancialnews.com/2019/05/16/viking-therapeutics-vktx-trading-up-5-3.html.

Viking Therapeutics Company Profile (NASDAQ:VKTX)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.

Featured Story: Net Margin

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.